2015-06-05 18:31:18 UTC

IBD Treatment

Clinical Snapshots

About

This AGA Clinical Snapshot is an executive summary of Dr. Sandborn's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.

Takeaways

1. Understand near-term and intermediate-term potential treatment options for patients who are failing currently available immunosuppressive and biologic therapy.

2. Many patients fail biologic therapy with anti-TNF agents and anti-integrin therapy with vedolizumab (anti-α4β7 antibody), through a variety of mechanisms including primary non-response, secondary lost response, and intolerance.

3. Treatment options switching within and out of class with alternative selective anti-integrin agents, sphingosine 1 phosphate (S1P) receptor modulators, Janus kinase (JAK) inhibitors, anti-interleukin 12/23 and anti- IL 23, and Smad7 antisense.

About the Instructors

William J. Sandborn, MD, AGAF, University of California, San Diego

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

What are the Future Selective Anti-integrin Therapies in Addition to the Currently Available Agent Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease?

In addition to the approved agent vedolizumab, there are three selective anti-integrin agents in development, anti-MAdCAM1 (PF-00547, 659, Pfizer), etrolizumab (anti-β7, rhumab beta 7, Genentech), anti-α4β7 (AMG181, Amgen) …

More on Crohn's Disease

Crohn's & Colitis Congress™ (A Partnership of the Crohn's & Colitis Foundation and American Gastroenterological Association)

Jan. 18, 2018

Expand your knowledge, network with IBD leaders, spark innovative research and get inspired to improve patient care.

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Oct. 22, 2017

We investigated whether serum trough levels of vedolizumab, during the induction phase can determine whether patients need additional doses within 6 months.

Healing of Tonsillar Crohn’s Disease With Infliximab

Oct. 22, 2017